Amicus Therapeutics, Inc (FOLD) Dividend History

Amicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic disorders. They specialize in protein misfolding diseases, utilizing both small molecule chaperones and gene therapy approaches to treat conditions such as Fabry disease, Pompe disease, and other lysosomal storage disorders. The company aims to leverage innovative science to address unmet medical needs in the rare disease community.

3675 Market Street, Philadelphia, PA, 19104
Phone: (215) 921-7600
Website: https://www.amicusrx.com

Dividend History

Amicus Therapeutics, Inc currently does not pay dividends

Company News

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Amicus Therapeutics announced the publication of a post-hoc analysis of data from the PROPEL study, which showed that patients with late-onset Pompe disease who switched from alglucosidase alfa to cipaglucosidase alfa-atga + miglustat experienced improvements or stability in most outcomes, while those who remained on alglucosidase alfa generally showed worsening or stability.

GlobeNewswire Inc.
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

Amicus Therapeutics, a global biotechnology company focused on rare diseases, announced that it will participate in upcoming investor conferences in June 2025.

GlobeNewswire Inc.
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

GlobeNewswire Inc.

Featured Companies: ABEO BCLI CAPR EDIT FDMT OCGN PFE RARE RGNX SGMO
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

Amicus Therapeutics, a global biotechnology company focused on rare diseases, will host a conference call on February 19, 2025, to discuss its financial results for the full-year ended December 31, 2024.

GlobeNewswire Inc.
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

Amicus Therapeutics, a biotechnology company, will present data on its Fabry and Pompe disease programs at the upcoming WORLDSymposium 2025 conference.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 22:23:29 UTC